Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 9/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.70 |
| ▸ | MEN1 | O00255 | 8/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.69 |
| ▸ | CTDSP1 | Q9GZU7 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | APEX1 | P27695 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.69 |
| ▸ | RECQL | P46063 | 2/20 | 0.69 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.69 |
| ▸ | MMP2 | P08253 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.66 |
| ▸ | PKM | P14618 | 3/20 | 0.66 |
| ▸ | PTGES | O14684 | 1/20 | 0.66 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46557 | 0.84 | MEN1 (0.70) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL29665060 | 0.84 | LCK (0.73) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6397407 | 0.82 | TDP1 (1.00) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6397410 | 0.82 | TDP1 (1.00) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL28362223 | 0.81 | EP300 (0.65) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL29361837 | 0.80 | POLB (0.88) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL31358741 | 0.80 | POLB (0.70) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL5145169 | 0.79 | KMT2A (0.88) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6395526 | 0.79 | KMT2A (0.88) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6393332 | 0.78 | POLB (0.71) | POLBKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115141274-B | Milk allergen beta-lactoglobulin specific nano-antibody and application thereof | 南开大学 | 2024-02-20 | — | — | CN | claimed |
| CN-115141274-A | Milk allergen beta-lactoglobulin specific nano antibody and application thereof | 南开大学 | 2022-10-04 | — | — | CN | claimed |
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4522628-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119552241-A | HIV-1 nano antibody, preparation method and application thereof | 上海市重大传染病和生物安全研究院 | 2025-03-04 | — | — | CN | disclosed |
| CN-115141274-B | Milk allergen beta-lactoglobulin specific nano-antibody and application thereof | 南开大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-115141274-B | Milk allergen beta-lactoglobulin specific nano-antibody and application thereof | 南开大学 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023220737-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-115141274-A | Milk allergen beta-lactoglobulin specific nano antibody and application thereof | 南开大学 | 2022-10-04 | — | — | CN | disclosed |
| CN-115141274-A | Milk allergen beta-lactoglobulin specific nano antibody and application thereof | 南开大学 | 2022-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | POLRMT, TARDBP, NSUN2 | POLB 20/4885KMT2A 1256/4885MEN1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.